| Document |
Document Title |
|
WO/2019/245047A1 |
The purpose of the present invention is to provide a technique for imaging the brain of a living animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain transferability, high recepto...
|
|
WO/2019/243422A1 |
The present disclosure relates to a solution comprising a water insoluble carbohydrate and a fluorescent dye, such as a near infrared (NIR) contrast agent, wherein the solution sets under aqueous conditions, such as in vivo, to form e.g....
|
|
WO/2019/243616A1 |
The invention provides a compound of formula (I), and salts, solvates and radiolabelled forms thereof, together with complexes of the compound of formula (I) with TSPO, and methods for forming such complexes, and methods for detecting th...
|
|
WO/2019/244072A1 |
The invention is directed to a body comprising an oxide of yttrium which is supported on a sulfur-containing carbon-based particle and to a process for producing said body.
|
|
WO/2019/235824A1 |
The present invention relates to a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression and a screening method therefor and, more particularly, to: a composition for diagnosing diseases associated wi...
|
|
WO/2019/237098A1 |
The present invention relates to biomarkers, methods and assay kits for predicting prognosis and/or monitoring progression of prostate cancer. The biomarkers include a glycosyltransferases [core 1 beta-3-galactosyltransferase (C1GALT1) a...
|
|
WO/2019/230905A1 |
The present invention addresses the problem of providing a halogenated biotin-modified dimer which allows imaging diagnosis or treatment by labeling, with a halogen element, a biotin-modified dimer which has a high affinity for a strepta...
|
|
WO/2019/232418A1 |
A molecular imaging agent including a detectable moiety, a chelation moiety, and a carrier moiety is provided. In one embodiment, the detectable moiety is coupled to the chelation moiety and the chelation moiety is linked to the carrier ...
|
|
WO/2019/222851A1 |
A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence ...
|
|
WO/2019/225296A1 |
A carrier for drug delivery use, comprising a human serum albumin variant in which a mannose-rich sugar chain having 8 or more mannose residues is bonded to a substance capable of interacting with the mannose-rich sugar chain or a bindin...
|
|
WO/2019/222454A1 |
This disclosure relates to styrylbenzothiazole derivatives for use as in vivo imaging agents for the diagnosis of Parkinson's disease (PD) or other degenerative disorders or conditions of the central nervous system. Early diagnosis is pa...
|
|
WO/2019/222653A1 |
Disclosed herein, inter alia, are silicon containing detectable compounds and methods of use thereof.
|
|
WO/2019/222713A1 |
A delivery assembly includes a console including a vial containment region and a vial engagement mechanism extending from the console within the vial containment region. The engagement mechanism is configured to engage a vial assembly. T...
|
|
WO/2019/222700A1 |
Multiphase microspheres for radioembolization include two-phase microspheres and three-phase microspheres prepared by a microfluidic process. The multiphase microspheres include a primary phase and a first secondary phase surrounded by t...
|
|
WO/2019/222680A1 |
In the present disclosure, embodiments of microbead containment systems and containment methods are disclosed. The microbead containment system may include a microsphere container, which includes walls that define a containment space in ...
|
|
WO/2019/222678A1 |
Methods and systems for determination of flow parameters of administered fluid from a radioembolization delivery device may include translationally moving a device delivery arm of the radioembolization delivery device in a translational ...
|
|
WO/2019/222681A1 |
Methods and systems for selection of dosimetry levels and sphere amounts of radioactive compounds for use in a radioembolization procedure for procedure planning may include inputting activity parameter information into a dosimetry porta...
|
|
WO/2019/221269A1 |
Provided are: a complex having an anti-human MUC1 antibody Fab fragment, a peptide linker and/or a ligand; a diagnostic composition and/or a medicinal composition comprising said complex; and a method for diagnosing and/or treating cance...
|
|
WO/2019/216223A1 |
The present invention provides compounds that accumulate at a high level in cardiac lesions and are suitable as a nuclear medicine tracer in PET imaging, enables in vivo detection of cardiac lesions by using said compounds, and provides ...
|
|
WO/2019/215207A1 |
The present disclosure relates to the delivery of active agents, e.g., drug substances, using as carriers for their delivery biocompatible copolymers comprising side chain-linked amino acids having active agents bound to their alpha-amin...
|
|
WO/2019/214681A1 |
Described herein are compounds of formula (I), and pharmaceutically acceptable salts, solvates, hydrates, isotopically labeled derivatives and radiolabeled derivative thereof, and pharmaceutical compositions thereof. Also provided are me...
|
|
WO/2019/213756A1 |
Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated ...
|
|
WO/2018/169356A9 |
The present invention relates to a pigment-coupled mannosyl serum albumin complex and a lymph node-probing composition comprising the same. More particularly, when administered to mice, a pigment-coupled mannosyl serum albumin complex ca...
|
|
WO/2019/216477A1 |
The present invention pertains to a novel liposome-based contrast agent that is for suppressing absorption in the reticuloendothelial system and for tumor-specific delivery of a radiolabeled substance. More specifically, the present inve...
|
|
WO/2019/210422A1 |
The present disclosure relates to Vitamin E derivatives as multi-scale imaging agents. In particular, the present disclosure relates to isotopically labeled Vitamin E derivatives, and their use as multi-scale imaging agents.
|
|
WO/2019/212356A1 |
Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield in vivo and high click release yields. In one aspect, the invention relates to kits comprising said tetrazines and a dienophile, prefer...
|
|
WO/2019/211843A1 |
A nanoparticle having a lipidic core, wherein the nanoparticle is linked via first polymeric linkers to a glucose molecules, and is further linked via second polymeric linkers to chelating agents, and wherein a weight ratio of the chelat...
|
|
WO/2019/212945A1 |
Described herein are systems and methods for particle-based photodynamic therapy (PDT) for the treatment of diseases such as cancer of the oral cavity and/or ovarian cancer metastases along the lining of the pelvis. The technology includ...
|
|
WO/2019/213456A1 |
The present disclosure provides methods of analyzing and/or purifying inorganic nanoparticles that may be functionalized with one or more dye group. Analyzing and/or purifying the inorganic nanoparticles includes utilizing liquid chromat...
|
|
WO/2019/207594A1 |
The present disclosure relates to development of ready to use microspheres (cold kit) for labeling with radionuclide. The present disclosure particularly relates to the development of radiolabeled microspheres and its application in pre ...
|
|
WO/2019/202399A1 |
The present application relates to antibodies which bind specifically to chelated radionuclides, including bispecific antibodies, It further relates to the use of such bispecific antibodies in applications such as radioimmunoimaging and ...
|
|
WO/2019/204335A1 |
The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a compound of the formula 1. The invention described her...
|
|
WO/2019/203191A1 |
The present invention relates to a labeling technique with which, without deterioration in the function of an antibody, metabolization in the liver after administration to a patient is facilitated and accumulation of radionuclides in org...
|
|
WO/2019/195890A1 |
Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine lig...
|
|
WO/2019/200005A1 |
A pharmaceutical composition that includes a compound of the structure: (I) to treat an HCV infected patient with cirrhosis, and uses thereof.
|
|
WO/2019/199998A1 |
Disclosed herein is a fractionated dosing regimen of 131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer.
|
|
WO/2019/195888A1 |
The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The c...
|
|
WO/2019/195541A1 |
Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target ...
|
|
WO/2019/195466A1 |
Provided herein are kits, compositions, and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a radioisotope, a gelatin matrix...
|
|
WO/2019/193464A1 |
A brachytherapy device (20, 21) including a base (22) adapted for being at least partially introduced into a body of a subject and a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the base in a manner that ...
|
|
WO/2019/190266A1 |
The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, capable of targeting PSMA, and a compound provided by one aspect of the present invention has a glutamine-urea-lysine compound to ...
|
|
WO/2019/186135A1 |
The present invention relates to radiolabelled olaparib and in particular [ 18 F]olaparib, a process for producing radiolabelled olaparib, and uses of radiolabelled olaparib in medical imaging.
|
|
WO/2019/180200A1 |
Complex compounds of transition metals according to formula (1) wherein the M(CO)3 + tricarbonyl-metal core forms a complex with the cyclopentadienyl anion linked to heterocyclic moieties of the benzothiazole, benzimidazole and benzoxazo...
|
|
WO/2019/181018A1 |
An oligosaccharide and an oligopeptide that exhibit an excellent ability to specifically bind to tumor cells and cancer cells and that can be simply and easily produced are chemically bonded to boron isotope (10B) nano-silica particles i...
|
|
WO/2019/183094A1 |
Chimeric antigen receptors (CARs) are provided that comprise a CD123-specific antigen recognition domain and IL7Ra transmembrane and intracellular signaling domains (CD123/IL7Ra CARs). In particular embodiments, provided herein are engin...
|
|
WO/2019/178677A1 |
The present disclosure relates to the targeted delivery of defined active agents and/or immunomodulatory agents to lymph nodes or lipoid cells in a lymphatic tissue. More particularly, the invention provides methods for targeted delivery...
|
|
WO/2019/181017A1 |
Provided is a novel boron isotope (10B) tracing drug for use in neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT). The novel boron isotope (10B) tracking-type drug represented by chemical formula 3 exhibits loc...
|
|
WO/2019/177449A1 |
The invention relates to a new lutetium-177 therapeutic radiopharmaceutical as an inhibitor of prostate-specific membrane antigen (iPSMA), wherein 1,4,7,10-tetraazacyclododecane-N,N´,N´´,N´´´´-tetraac
etic acid (DOTA) bonded to th...
|
|
WO/2019/175761A1 |
The present invention relates to a stable, multidose, ready to use, non-aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection; wherein dantrole...
|
|
WO/2019/175405A1 |
6-[18HF]Fluoro-2-alkoxynicotinoyl substituted Lys-C(O)-Glu derivatives were identified as efficient imaging probes for PSMA expressing tissues in comparison to other known PSMA specific ligands like [18F]DCFPyL, [68Ga]HBED-CC-PSMA, [18F]...
|
